Predict your next investment

Corporation
ELECTRONICS | Electronic Components
auxora.com

See what CB Insights has to offer

Founded Year

2000

Stage

Acquired | Acquired

Total Raised

$26.4M

About Auxora

Auxora aims to provide wavelength management and control solutions for the photonics industry through its NanoCODE technology. Its current products include tunable filters, DWDM filters (50 GHz and 100 GHz), and specialty thin film filters such as Gain Flattening Filters and high performance band splitters. Auxora is currently serving over 30 public and private customers in the US and abroad.In 2010, Auxora was acquired by Yongpu. The valuation of Auxora was undisclosed. Other terms of the deal were not released.

Auxora Headquarter Location

Floor 1&3, Building 5 Zhong Yun Tai Industrial Park 1 Tangtou road

Shenzhen, Guangdong,

China

(+86) 755-8601 6750

Latest Auxora News

CalciMedica’s drug lowers mortality rate in Phase II Covid-19 trial

Sep 15, 2021

15 Sep 2021 (Last Updated September 15th, 2021 09:44) Auxora was found to be well-tolerated, with a smaller proportion of subjects in the Auxora arm experiencing serious adverse events. Share Article Auxora is an intravenous formulated small molecule currently being developed to treat Covid-19. CalciMedica has reported top-line results from the Phase II CARDEA clinical trial of its lead drug candidate, Auxora, in severe Covid-19 pneumonia patients. Auxora is an intravenous (IV) formulated small molecule that selectively inhibits the calcium release-activated calcium (CRAC) channel. The drug hinders acute epithelial and endothelial cell injury and inflammation in organs, including the pancreas and lungs. The randomised, double-blind, placebo-controlled Phase II trial enrolled 284 Covid-19 pneumonia patients who were in the hospital and receiving supplemental oxygen through a high flow nasal cannula or low flow device. Initially, the company planned to enrol up to 400 subjects, but the enrolment was halted owing to the reduced number of Covid-19 cases and hospitalisations. CalciMedica also attributed the halt to modifications in the standard of care (SOC) that comprised immunosuppressive therapies not included in the trial protocol. The trial randomised 281 subjects in a 1:1 ratio to receive a minimum of one dose of either Auxora plus SOC or placebo plus SOC. It had 261 subjects with moderate or severe respiratory failure and 23 participants with mild respiratory failure. All subjects received SOC treatment with corticosteroids and more than 99% also received prophylactic anticoagulation treatment. The time to recovery through day 60 was the trial’s primary goal. In the 261-subject efficacy dataset, the median time to recovery was seven days for subjects in the Auxora arm versus ten days in the placebo arm, indicating a recovery ratio of 1.25. In the 281-subject safety dataset, the median time to recovery was seven days for subjects receiving Auxora as against eight days in the placebo arm, signifying a recovery ratio of 1.30. On the key secondary goal of all-cause mortality by day 60 and a supportive secondary goal of all-cause mortality by day 30 assessed in the 261-subject efficacy dataset, Auxora attained statistical significance. In the Auxora arm, the 30-day all-cause mortality was 7.7% versus 17.6% for placebo, showing a 56% relative risk reduction and 9.9% absolute risk reduction for mortality. The 60-day all-cause mortality was 13.8% in the Auxora group as against 20.6% in the placebo arm, indicating a 33% and 6.8% relative mortality risk reduction and absolute mortality risk reduction, respectively. Findings also showed that Auxora was well-tolerated with a reduced proportion of 24.1% of subjects in the drug arm experiencing serious adverse events (SAEs) versus 35% in the placebo arm. CalciMedica chief medical officer Sudarshan Hebbar said: “Initial efficacy signals for both time to recovery and mortality in CARDEA suggest that Auxora may rapidly reduce inflammation and reduce damage to vital organ tissue—both key in the fight against disease progression. “These signals were observed even though we did not power the study for mortality endpoints, and we decided to halt enrolment before reaching our target.” The company plans to discuss the trial results with the US Food and Drug Administration (FDA) and to assess additional opportunities to evaluate Auxora in Covid-19 patients.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Auxora Patents

Auxora has filed 5 patents.

The 3 most popular patent topics include:

  • Fiber optics
  • Ethernet
  • Multiplexing
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/17/2019

11/3/2020

Fiber optics, Network protocols, Ethernet, Multiplexing, Optical devices

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

10/17/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

11/3/2020

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Fiber optics, Network protocols, Ethernet, Multiplexing, Optical devices

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.